JP2024524159A5 - - Google Patents
Info
- Publication number
- JP2024524159A5 JP2024524159A5 JP2023578073A JP2023578073A JP2024524159A5 JP 2024524159 A5 JP2024524159 A5 JP 2024524159A5 JP 2023578073 A JP2023578073 A JP 2023578073A JP 2023578073 A JP2023578073 A JP 2023578073A JP 2024524159 A5 JP2024524159 A5 JP 2024524159A5
- Authority
- JP
- Japan
- Prior art keywords
- myostatin
- glp
- analog
- selective inhibitor
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163214234P | 2021-06-23 | 2021-06-23 | |
| US63/214,234 | 2021-06-23 | ||
| US202163260136P | 2021-08-10 | 2021-08-10 | |
| US63/260,136 | 2021-08-10 | ||
| US202163260254P | 2021-08-13 | 2021-08-13 | |
| US63/260,254 | 2021-08-13 | ||
| US202263266348P | 2022-01-03 | 2022-01-03 | |
| US63/266,348 | 2022-01-03 | ||
| US202263269702P | 2022-03-21 | 2022-03-21 | |
| US63/269,702 | 2022-03-21 | ||
| PCT/US2022/034588 WO2022271867A1 (en) | 2021-06-23 | 2022-06-22 | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024524159A JP2024524159A (ja) | 2024-07-05 |
| JP2024524159A5 true JP2024524159A5 (https=) | 2025-06-18 |
Family
ID=82608742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023578073A Pending JP2024524159A (ja) | 2021-06-23 | 2022-06-22 | 代謝障害の治療における使用のためのｇｌｐ－１経路活性化剤と組み合わせたミオスタチン経路阻害剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240368262A1 (https=) |
| EP (2) | EP4714494A3 (https=) |
| JP (1) | JP2024524159A (https=) |
| AU (1) | AU2022299185A1 (https=) |
| CA (1) | CA3221555A1 (https=) |
| DK (1) | DK4358995T3 (https=) |
| ES (1) | ES3062188T3 (https=) |
| FI (1) | FI4358995T3 (https=) |
| IL (1) | IL309078A (https=) |
| MX (1) | MX2023014840A (https=) |
| PL (1) | PL4358995T3 (https=) |
| PT (1) | PT4358995T (https=) |
| SI (1) | SI4358995T1 (https=) |
| TW (1) | TW202317175A (https=) |
| WO (1) | WO2022271867A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20211081T1 (hr) | 2015-09-15 | 2021-10-15 | Scholar Rock, Inc. | Anti-pro/latentna miostatinska protutijela i njihove uporabe |
| WO2024064842A1 (en) * | 2022-09-21 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
| EP4638496A1 (en) | 2022-12-22 | 2025-10-29 | Scholar Rock, Inc. | Selective and potent inhibitory antibodies of myostatin activation |
| WO2025027052A1 (en) * | 2023-07-31 | 2025-02-06 | Sixpeaks Bio Ag | Antibody conjugates and fusion proteins |
| WO2025219859A1 (en) * | 2024-04-14 | 2025-10-23 | Biohaven Therapeutics Ltd. | Combination therapy to treat overweight, obesity, and related health conditions |
| WO2025227129A2 (en) | 2024-04-25 | 2025-10-30 | Starrock Pharma Llc | Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof |
| WO2025245160A1 (en) | 2024-05-21 | 2025-11-27 | Scholar Rock, Inc. | Myostatin-selective inhibitors for treating metabolic disorders |
| WO2026037938A1 (en) * | 2024-08-16 | 2026-02-19 | Protuoso Pte. Ltd. | Fusion proteins comprising a glp-1 receptor agonist and a myostatin pathway inhibitor |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| EP1820858B1 (en) | 1991-03-01 | 2009-08-12 | Dyax Corporation | Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| WO2000053211A2 (en) | 1999-03-09 | 2000-09-14 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| KR101704893B1 (ko) | 2012-06-15 | 2017-02-08 | 화이자 인코포레이티드 | Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도 |
| RS61778B1 (sr) | 2013-05-06 | 2021-06-30 | Scholar Rock Inc | Kompozicije i postupci za modulaciju faktora rasta |
| EP3215175A4 (en) | 2014-11-06 | 2018-06-27 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| HRP20211081T1 (hr) | 2015-09-15 | 2021-10-15 | Scholar Rock, Inc. | Anti-pro/latentna miostatinska protutijela i njihove uporabe |
| AR107078A1 (es) | 2015-12-18 | 2018-03-21 | Chugai Pharmaceutical Co Ltd | Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso |
| CN115814077A (zh) | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| NZ789269A (en) | 2016-06-13 | 2026-01-30 | Scholar Rock Inc | Use of myostatin inhibitors and combination therapies |
| JOP20190152A1 (ar) * | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| EP4218817A3 (en) * | 2017-01-06 | 2023-09-06 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
| PT3565592T (pt) * | 2017-01-06 | 2023-05-31 | Scholar Rock Inc | Tratamento de doenças metabólicas através da inibição da ativação da miostatina |
| WO2019193204A1 (en) * | 2018-04-06 | 2019-10-10 | Cyprumed Gmbh | Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins |
| CN113677711B (zh) * | 2019-01-30 | 2025-05-30 | 供石公司 | TGFβ的LTBP复合特异性抑制剂及其用途 |
-
2022
- 2022-06-22 CA CA3221555A patent/CA3221555A1/en active Pending
- 2022-06-22 PT PT227440542T patent/PT4358995T/pt unknown
- 2022-06-22 DK DK22744054.2T patent/DK4358995T3/da active
- 2022-06-22 WO PCT/US2022/034588 patent/WO2022271867A1/en not_active Ceased
- 2022-06-22 FI FIEP22744054.2T patent/FI4358995T3/fi active
- 2022-06-22 IL IL309078A patent/IL309078A/en unknown
- 2022-06-22 EP EP25220159.5A patent/EP4714494A3/en active Pending
- 2022-06-22 ES ES22744054T patent/ES3062188T3/es active Active
- 2022-06-22 SI SI202230232T patent/SI4358995T1/sl unknown
- 2022-06-22 US US18/572,397 patent/US20240368262A1/en active Pending
- 2022-06-22 MX MX2023014840A patent/MX2023014840A/es unknown
- 2022-06-22 AU AU2022299185A patent/AU2022299185A1/en active Pending
- 2022-06-22 JP JP2023578073A patent/JP2024524159A/ja active Pending
- 2022-06-22 EP EP22744054.2A patent/EP4358995B1/en active Active
- 2022-06-22 PL PL22744054.2T patent/PL4358995T3/pl unknown
- 2022-06-23 TW TW111123506A patent/TW202317175A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024524159A5 (https=) | ||
| FI4358995T3 (fi) | Mystostatiinireitin estäjä yhdessä glp-1-reitin aktivaattorin kanssa käytettäviksi metabolisten häiriöiden hoidossa | |
| JP2020516647A5 (https=) | ||
| TW202323296A (zh) | 組合療法 | |
| JP2020536097A5 (https=) | ||
| JP2021193121A (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| JP7663559B2 (ja) | Ａｃｔｒｉｉ受容体拮抗薬を含む肝疾患または肝臓障害の治療 | |
| EP2686014A1 (en) | Uses of a dual v region antibody-like protein | |
| CN116390756A (zh) | 抗前肌生成抑制蛋白/潜伏性肌生成抑制蛋白抗体用于治疗脊髓性肌萎缩的用途 | |
| WO2021255621A1 (en) | Treatment of food allergy using anti-ige antibodies | |
| WO2023231730A2 (zh) | 使用mazdutide的治疗方法 | |
| AU2024202601A1 (en) | Method of treating tendinopathy using interleukin-17 (IL-17) antagonists | |
| JP2025514978A (ja) | 脊髄性筋萎縮症を治療するためのミオスタチン阻害薬の使用 | |
| JP2024544380A (ja) | 抗ＩｇＥ抗体を使用したアレルギー反応の治療 | |
| CA2788758A1 (en) | Treatment of a metabolic disorder | |
| JP2023527054A5 (https=) | ||
| CN113195532B (zh) | 使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法 | |
| CN113474363A (zh) | 用于降低体重和/或减少食物摄取量的gdf15类似物和方法 | |
| EA006881B1 (ru) | ПРИМЕНЕНИЕ АКТИВАТОРОВ gp130 ПРИ ДИАБЕТИЧЕСКОЙ НЕВРОПАТИИ | |
| Khan | Recombinant interferon alpha-2b is a high-affinity antigen for type 1 diabetes autoantibodies | |
| CN108992671B (zh) | 一种药物组合物及其制备治疗肝损伤的药物中的用途 | |
| AU2021293980B2 (en) | Treatment of food allergy using anti-IgE antibodies | |
| RU2838150C1 (ru) | Лечение заболевания или нарушения со стороны печени, предусматривающее применение антагонистов рецепторов actrii | |
| WO2025120567A1 (en) | Method of treatment of asthma | |
| TW202545540A (zh) | 用於治療ａｐｏｌ１介導之腎病之方法 |